Full Text View
Tabular View
No Study Results Posted
Related Studies
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
This study is currently recruiting participants.
Verified December 2013 by National Institutes of Health Clinical Center (CC)
Study NCT01212094   Information provided by National Institutes of Health Clinical Center (CC)

First Received on September 29, 2010.   Last Updated on March 14, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
More general drug interventions related to this trial
Sponsors listed in this trial